Johnson & Johnson presents findings from the largest European real-world dataset for esketamine nasal spray (NS) which confirm its effectiveness and tolerability in a real-world patient population, which on average had severe, chronic, treatment-resistant depression (TRD). The study offers distinct new insight into the durability of treatment effect, with symptom stability maintained across 6 months following discontinuation of esketamine NS.